VolitionRX Ltd
VNRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.1M
Close$
$1.02
471.1% upside
Current Fair Value
471.1% upsideUndervalued by 471.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.10 Million |
|---|---|
| Enterprise Value | $1.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.4 |
| Beta | 1.17 |
| Outstanding Shares | 9,154,815 |
Return
| Return on Equity | 127.90% |
|---|---|
| Return on Assets | -308.88% |
| Return on Invested Capital | -264.57% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.27 |
| Price to Sales | - |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | 0.51 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.55 |
| Debt to Equity | -0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$1.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$706,438
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.90%▼ 20.19% |
|---|---|
| Total Invested | $21,321▼ 99.18% |
| Investors Holding | 4▼ 22.00% |
ESG Score
No data
About VolitionRX Ltd
65 employeesVolition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients...